At Thermo Fisher Scientific, we have developed advanced next-generation sequencing solutions to address key challenges in the molecular analysis of hematologic malignancies.
Watch our virtual symposium on demand to learn how we can help simplify your path to answers in the study of myeloid and lymphoid cancer.
Speaker:
Dr. Diana Morlote
University of Alabama at Birmingham
During this presentation, Dr. Diana Morlote, assistant professor of pathology at the University of Alabama at Birmingham, will discuss the recent implementation of a rapid, automated next-generation sequencing (NGS) assay in her research laboratory for genomic profiling of Acute Myeloid Leukemia (AML) and other related hematological disorders. The data collected from several cases using the Oncomine Myeloid Assay GX v2 by Thermo Fisher Scientific will be presented. Analytical performance will be discussed for various key mutations detected using DNA inputs. Morlote will describe how this solution addresses key challenges with molecular analysis of AML and other related malignancies. This research furthers our understanding of malignant hematological disorders and may lead to better care in the future.
The Ion Torrent Genexus System is the first turnkey next-generation sequencing (NGS) solution that automates the end-to-end workflow from the biological specimen all the way to the final report and delivers results in as little as a single day.
Request a quote or personal demonstration from a Thermo Fisher Scientific representative.
